Johns Hopkins Technology Ventures

Attention female innovators and business moguls at JHU! Applications for Equalize Startups are due this Friday, November 15! Join a comprehensive entrepreneurship program for academic women inventors who want to commercialize their innovations.

Eligibility Requirements:
An academic appointment (tenured, tenure track, or research) or a post-doc or graduate student at an academic research institution.
Must have a pending or issued patent or copyright.

Elevate your entrepreneurial journey and unlock a world of opportunities designed just for you! Apply now: https://tinyurl.com/y9ptad3x

We’re excited to announce the release of JHTV’s annual report for Fiscal Year 2024! This year, we celebrate ten years of unwavering dedication to our talented faculty and students. We invite you to take a moment to celebrate our progress, achievements, and the inventors driving innovation within the Johns Hopkins entrepreneurial community.

We deeply appreciate the many stakeholders who make this possible as we look to build on our successes in FY25 and onward!
https://ventures.jhu.edu/news/explore-jhtvs-fy24-annual-report/

Johns Hopkins University, Techstars, and CareFirst BlueCross BlueShield are teaming up to launch the Techstars AI Health Baltimore accelerator program. This initiative will empower early-stage entrepreneurs to revolutionize healthcare through AI. With the combined expertise in this collaboration, the program aims to bring more entrepreneurs and startup activity to the Baltimore ecosystem and drive high-impact healthcare innovation to market.

The 13-week program will take place in-person in Baltimore and will focus on supporting entrepreneurs leading healthtech, medtech, and biotech startups. Applications open August 26.

https://ventures.jhu.edu/news/techstars-johns-hopkins-university-and-carefirst-bluecross-blueshield-to-bring-healthcare-a-i-accelerator-to-baltimore/

Great to see one of Johns Hopkins Technology Ventures & Johns Hopkins Applied Physics Lab startups Oculi listed as one of EE|Times's 100 startups to watch!
https://bit.ly/4dgs23M

A groundbreaking new therapy was approved by the FDA on August 6th, leveraging cancer research conducted at the Johns Hopkins Kimmel Cancer Center. Vorasidenib is a treatment for a particularly lethal type of brain cancer, called low-grade glioma. There has been little hope for those undergoing treatment for glioma – until now. https://bit.ly/3yvtCQ2

Our Maryland-Virginia-Washington DC Biohealth Capital Region has been ranked third in the nation, following San Francisco and Boston, among the top 10 Biopharma Clustershttps://www.genengnews.com/a-lists/top-10-u-s-biopharma-clusters-10/

Our July Newsletter is out! Check out our new video interview and Q&A with faculty investigators, along with exciting updates from our startup community and broader ecosystem! https://bit.ly/3SukfqC Kubanda Cryotherapy Leonardo DRS Rapafusyn Pharmaceuticals

New gene-editing approach offers hope to sickle cell patients! Xizhen Lian, assistant research scientist affiliated with Johns Hopkins Whiting School of Engineering, the NanoBioTechnology Institute & Johns Hopkins Medicine, says "This gene editing approach would allow patients to receive the medicine through a transfusion." https://bit.ly/4c6OJ9b

Unique among universities, Johns Hopkins' research development team stands out by assisting faculty in securing large-scale grants through their personal and tailored proposal development support and thoughtful fostering of collaboration across disciplines. https://bit.ly/4bXQRQt

New Johns Hopkins Technology Ventures office hours this acadmic year, just down the hall from the CS Department—check them out!

A remarkable advance has been made at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy: Using genetic engineering techniques, a team of investigators, including those from JH Tech Ventures, have designed a novel type of cell to recognize and fight cancer. https://bit.ly/4fk6ODm